FDA Hits Arog Pharmaceuticals With Untitled Letter Over Promotional Tactics

Drug Industry Daily
A A
The FDA issued an untitled letter to Arog Pharmaceuticals for promotional claims it made on a display booth and a webpage about an unapproved investigational new drug’s safety and efficacy.

To View This Article:

Login

Subscribe To Drug Industry Daily